ARS Pharmaceuticals, Inc. SPRY

About ARS Pharmaceuticals, Inc. (SPRY): stock profile, AI score and financials

ARS Pharmaceuticals, Inc. (SPRY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SPRY at 26.8/100 on a composite quality score built from its SEC filings, placing it at rank #2,576 of 2,925 stocks — the bottom half of the AI-ranked universe. SPRY scores in the top quartile across revenue growth (99.4). Areas of concern include balance sheet strength (1.8) and free cash flow (5.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ARS Pharmaceuticals, Inc. reports quarterly revenue of $33.7M, net income of $-62.3M, an operating margin of -182.6%. SPRY trades on the Nasdaq exchange and files with the SEC under CIK 1671858. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SPRY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ARS Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1671858 →